Momordica charantia administration improves insulin secretion in type 2 diabetes mellitus

Journal of Medicinal Food

Volumn 21, Issue 7, 2018, Pages 672-677

  Cortez Navarrete, Marisol ^a   Martínez Abundis, Esperanza ^a   Pérez Rubio, Karina G ^a   González Ortiz, Manuel ^a   Méndez Del Villar, Miriam ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

insulin secretion; insulin sensitivity; Momordica charantia; nutraceutic; type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; PLANT EXTRACT;

ABDOMINAL DISTENSION; ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIETARY SUPPLEMENT; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOMORDICA CHARANTIA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDENTIAL AREA; SOCIAL STATUS; WAIST CIRCUMFERENCE; CHEMISTRY; GLUCOSE TOLERANCE TEST; METABOLISM; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MOMORDICA CHARANTIA; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 85050255535     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2017.0114     Document Type: Article

References (33)

1. International Diabetes Federation: The Global Burden, www.idf. org/diabetesatlas; 2015 (accessed February 19, 2017).
2. American Diabetes Association: Standards of medical care in diabetes 2017. Diabetes Care 2017;40:S11-S65.
3. Leung L, Birtwhistle R, Kotecha J, et al.: Antidiabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br J Nutr 2009;102:1703-1708.
4. Chaturved P, George S: Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food 2010; 13:520-527.
5. Virdi J, Sivakami S, Shahani S, et al.: Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 2003;88:107-111.
6. Klomann SD, Mueller AS, Pallauf J, et al.: Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br J Nutr 2010;104:1613-1620.
7. Clouatre DL, Rao SN, Preuss HG: Bitter melon extracts in diabetic and normal rats favorably influence blood glucose and blood pressure regulation. J Med Food 2011;14:1496-1504.
8. Ojewole JA, Adewole SO, Olayiwola G: Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr 2006;17: 227-232.
9. Ahmed I, Lakhani MS, Gillett M, et al.: Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2001;51:155-161.
10. Chen PH, Chen GC, Yang MF, et al.: Bitter melon seed oil attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue. J Nutr 2012;142:1197-1204.
11. Chan LL, Chen Q, Go AG, et al.: Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 2005;135:2517-2523.
12. Rahman I, Khan R, Rahman K, et al.: Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J 2015;14:13-28.
13. Fuangchan A, Seubnukarn T, Jungpattanawadee D, et al.: Retrospective study on the use of bitter melon for type 2 diabetes at Dansai Crown Prince Hospital, Thailand. Srinagarind Med J 2009;24:332-338.
14. Fuangchan A, Sonthisombat P, Seubnukarn T, et al.: Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 2011;13: 422-428.
15. Lim TS, Jimeno CA, Razon-Gonzales EB, et al.: The MOCHA DM study: The effect of Momordica charantia tablets on glucose and insulin levels during the postprandial state among patients with type 2 diabetes mellitus. Philipp J Intern Med 2010;48: 19-25.
16. Tsai CH, Chen EC, Tsay HS, et al.: Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial. Nutr J 2012;11:4-13.
17. Stumvoll M, Mitrakou A, Pimienta W, et al.: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.
18. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
19. Jeyaseelan L, Rao PSS: Methods of determining sample sizes in clinical trials. Indian Pediatr 1989;26:115-121.
20. Oka R, Yagi K, Sakurai M, et al.: Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middleaged Japanese. Endocr J 2012;59:55-64.
21. Ahmed I, Adeghate E, Cummings E, et al.: Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 2004;261:63-70.
22. Hafizur RM, Kabir N, Chisti S: Modulation of pancreatic b-cells in neonatally streptozotocin-induced type-2 diabetic rats by the ethanolic extract of Momordica charantia fruit pulp. Nat Prod Res 2011;25:353-367.
23. Abdollahi M, Zuki AB, Goh YM, et al.: Effects of Momordica charantia on pancreatic histopathological changes associated with streptozotocin-induced diabetes in neonatal rats. Histol Histopathol 2011;26:13-21.
24. Singh N, Gupta M: Regeneration B-cells in islets of Langerhans of pancrease of alloxan diabetic rats by acetone extract of Momordica charantia (Linn) (bitter gourd) fruits. Indian J Exp Biol 2007;45:1055-1062.
25. Yibchok-anun S, Adisakwattana S, Yao CY, et al.: Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulin mimetic activities. Biol Pharm Bull 2006;29:1126-1131.
26. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, et al.: Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulinstimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr 2008; 99:806-812.
27. Nerurkar PV, Lee YK, Motosue M, et al.: Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 2008;100:751-759.
28. McCarty MF: Does bitter melon contain an activator of AMPactivated kinase? Med Hypotheses 2004;63:340-343.
29. Tan MJ, Ye JM, Turner N, et al.: Antidiabetic activities of triterpenoids isolated from bitter melon associated with the activation of AMPK pathway. Chem Biol 2008;15:263-273.
30. Chaturvedi P: Antidiabetic potentials of Momordica charantia: Multiple mechanisms behind the effects. J Med Food 2012;15: 101-107.
31. Picard F, Auwerx J: PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-197.
32. Gutch M, Kumar S, Razi SM, et al.: Assessment of insulin sensitivity/ resistance. Indian J Endocrinol Metab 2015;19:160-164.
33. Nerurkar PV, Lee YK, Nerurkar VR: Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010;10:34-44.